730 related articles for article (PubMed ID: 30665034)
41. Discovery of novel pyrrolopyrimidine/pyrazolopyrimidine derivatives bearing 1,2,3-triazole moiety as c-Met kinase inhibitors.
Wang L; Liu X; Duan Y; Li X; Zhao B; Wang C; Xiao Z; Zheng P; Tang Q; Zhu W
Chem Biol Drug Des; 2018 Jul; 92(1):1301-1314. PubMed ID: 29575727
[TBL] [Abstract][Full Text] [Related]
42. Synthesis, Biological Evaluation and In Silico Studies of Certain Oxindole-Indole Conjugates as Anticancer CDK Inhibitors.
Al-Warhi T; El Kerdawy AM; Aljaeed N; Ismael OE; Ayyad RR; Eldehna WM; Abdel-Aziz HA; Al-Ansary GH
Molecules; 2020 Apr; 25(9):. PubMed ID: 32349307
[TBL] [Abstract][Full Text] [Related]
43. EGFR inhibitors and apoptotic inducers: Design, synthesis, anticancer activity and docking studies of novel xanthine derivatives carrying chalcone moiety as hybrid molecules.
Abou-Zied HA; Youssif BGM; Mohamed MFA; Hayallah AM; Abdel-Aziz M
Bioorg Chem; 2019 Aug; 89():102997. PubMed ID: 31136902
[TBL] [Abstract][Full Text] [Related]
44. Molecular docking approach for the design and synthesis of new pyrazolopyrimidine analogs of roscovitine as potential CDK2 inhibitors endowed with pronounced anticancer activity.
Hamed OA; Abou-Elmagd El-Sayed N; Mahmoud WR; F Elmasry G
Bioorg Chem; 2024 Jun; 147():107413. PubMed ID: 38696844
[TBL] [Abstract][Full Text] [Related]
45. Design and synthesis of novel pyridopyrimidine derivatives with anchoring non-coplanar aromatic extensions of EGFR inhibitory activity.
Eissa AAM; Aljamal KFM; Ibrahim HS; Abdelrasheed Allam H
Bioorg Chem; 2021 Nov; 116():105318. PubMed ID: 34488123
[TBL] [Abstract][Full Text] [Related]
46. Design and synthesis of novel tranilast analogs: Docking, antiproliferative evaluation and in-silico screening of TGFβR1 inhibitors.
Ismail MMF; El-Zahabi HSA; Ibrahim RS; Mehany ABM
Bioorg Chem; 2020 Dec; 105():104368. PubMed ID: 33091671
[TBL] [Abstract][Full Text] [Related]
47. Design, synthesis and biological evaluation of novel N-(3-amino-4-methoxyphenyl)acrylamide derivatives as selective EGFR
Ding S; Dong X; Gao Z; Zheng X; Ji J; Zhang M; Liu F; Wu S; Li M; Song W; Shen J; Duan W; Liu J; Chen Y
Bioorg Chem; 2022 Jan; 118():105471. PubMed ID: 34798457
[TBL] [Abstract][Full Text] [Related]
48. Development of pyridazine derivatives as potential EGFR inhibitors and apoptosis inducers: Design, synthesis, anticancer evaluation, and molecular modeling studies.
Ahmed MF; Santali EY; Mohi El-Deen EM; Naguib IA; El-Haggar R
Bioorg Chem; 2021 Jan; 106():104473. PubMed ID: 33243490
[TBL] [Abstract][Full Text] [Related]
49. Design and synthesis of new benzoxazole/benzothiazole-phthalimide hybrids as antitumor-apoptotic agents.
Philoppes JN; Lamie PF
Bioorg Chem; 2019 Aug; 89():102978. PubMed ID: 31136900
[TBL] [Abstract][Full Text] [Related]
50. Novel scaffold hopping of potent benzothiazole and isatin analogues linked to 1,2,3-triazole fragment that mimic quinazoline epidermal growth factor receptor inhibitors: Synthesis, antitumor and mechanistic analyses.
Rezki N; Almehmadi MA; Ihmaid S; Shehata AM; Omar AM; Ahmed HEA; Aouad MR
Bioorg Chem; 2020 Oct; 103():104133. PubMed ID: 32745759
[TBL] [Abstract][Full Text] [Related]
51. New 2-alkoxycyanopyridine derivatives as inhibitors of EGFR, HER2, and DHFR: Synthesis, anticancer evaluation, and molecular modeling studies.
Hawas SS; El-Sayed SM; Elzahhar PA; Moustafa MA
Bioorg Chem; 2023 Dec; 141():106874. PubMed ID: 37769524
[TBL] [Abstract][Full Text] [Related]
52. Discovery of novel pyrazolo[3,4-b]pyridine scaffold-based derivatives as potential PIM-1 kinase inhibitors in breast cancer MCF-7 cells.
Nafie MS; Amer AM; Mohamed AK; Tantawy ES
Bioorg Med Chem; 2020 Dec; 28(24):115828. PubMed ID: 33166925
[TBL] [Abstract][Full Text] [Related]
53. Novel oxindole/benzofuran hybrids as potential dual CDK2/GSK-3β inhibitors targeting breast cancer: design, synthesis, biological evaluation, and
Eldehna WM; Al-Rashood ST; Al-Warhi T; Eskandrani RO; Alharbi A; El Kerdawy AM
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):270-285. PubMed ID: 33327806
[TBL] [Abstract][Full Text] [Related]
54. Novel piperazine-chalcone hybrids and related pyrazoline analogues targeting VEGFR-2 kinase; design, synthesis, molecular docking studies, and anticancer evaluation.
Ahmed MF; Santali EY; El-Haggar R
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):307-318. PubMed ID: 33349069
[TBL] [Abstract][Full Text] [Related]
55. Design, synthesis, antiproliferative activity, molecular docking and cell cycle analysis of some novel (morpholinosulfonyl) isatins with potential EGFR inhibitory activity.
Ammar YA; Sh El-Sharief AM; Belal A; Abbas SY; Mohamed YA; Mehany ABM; Ragab A
Eur J Med Chem; 2018 Aug; 156():918-932. PubMed ID: 30096580
[TBL] [Abstract][Full Text] [Related]
56. Synthesis and biological evaluation of 2-styrylquinolines as antitumour agents and EGFR kinase inhibitors: molecular docking study.
El-Sayed MA; El-Husseiny WM; Abdel-Aziz NI; El-Azab AS; Abuelizz HA; Abdel-Aziz AA
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):199-209. PubMed ID: 29251017
[TBL] [Abstract][Full Text] [Related]
57. Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors.
Sever B; Altıntop MD; Radwan MO; Özdemir A; Otsuka M; Fujita M; Ciftci HI
Eur J Med Chem; 2019 Nov; 182():111648. PubMed ID: 31493743
[TBL] [Abstract][Full Text] [Related]
58. Synthesis, molecular modeling and anti-cancer evaluation of a series of quinazoline derivatives.
Khodair AI; Alsafi MA; Nafie MS
Carbohydr Res; 2019 Dec; 486():107832. PubMed ID: 31622868
[TBL] [Abstract][Full Text] [Related]
59. Azole-hydrazone derivatives: Design, synthesis, in vitro biological evaluation, dual EGFR/HER2 inhibitory activity, cell cycle analysis and molecular docking study as anticancer agents.
Labib MB; Philoppes JN; Lamie PF; Ahmed ER
Bioorg Chem; 2018 Feb; 76():67-80. PubMed ID: 29153588
[TBL] [Abstract][Full Text] [Related]
60. Synthesis of Novel Thieno[2,3-d]pyrimidine Derivatives and Evaluation of Their Cytotoxicity and EGFR Inhibitory Activity.
Adly ME; Gedawy EM; El-Malah AA; El-Telbany FA
Anticancer Agents Med Chem; 2018; 18(5):747-756. PubMed ID: 29366427
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
